M Beat 50 Tablet ER contains Metoprolol Succinate 50 mg, a cardioselective beta-1 adrenergic receptor blocker used primarily in the management of hypertension, angina pectoris, and heart failure. By selectively inhibiting beta-1 receptors in the heart, Metoprolol reduces heart rate, myocardial contractility, and cardiac output, thereby decreasing oxygen demand and lowering blood pressure. The extended-release formulation ensures a sustained therapeutic effect, allowing once-daily dosing and improved patient compliance. M Beat 50 is indicated for the treatment of essential hypertension to reduce the risk of cardiovascular events, management of stable angina to prevent anginal attacks, and as part of heart failure therapy to improve survival and reduce hospitalizations. It is also employed in the prevention of myocardial infarction and in controlling arrhythmias. Patients with asthma, severe bradycardia, or overt cardiac failure should use this medication cautiously under medical supervision. Common adverse effects may include fatigue, dizziness, hypotension, and gastrointestinal disturbances. Dose adjustments may be necessary in renal or hepatic impairment. M Beat 50 Tablet ER should be administered as prescribed, with gradual dose titration to minimize adverse effects. Regular monitoring of heart rate, blood pressure, and clinical status is recommended to ensure optimal therapeutic outcomes.